Supernus Pharmaceuticals, Inc. (SUPN)
$
31.98
-0.09 (-0.28%)
Key metrics
Financial statements
Free cash flow per share
2.9239
Market cap
1.7 Billion
Price to sales ratio
2.6117
Debt to equity
0.0313
Current ratio
2.4402
Income quality
2.6512
Average inventory
51.9 Million
ROE
0.0614
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of products aimed at treating central nervous system (CNS) diseases in the United States. The net total of other income and expenses is $16,204,000.00 reflecting non-core financial activities. The financial data pertains to the fiscal year 2024. Its commercial portfolio includes Trokendi XR, an extended-release topiramate formulation for epilepsy treatment and migraine headache prophylaxis, as well as Oxtellar XR, which serves as a monotherapy for partial onset epilepsy seizures in both adults and children aged 6 to 17. Other products from the company include Qelbree, a selective norepinephrine reuptake inhibitor for attention-deficit hyperactivity disorder (ADHD) in pediatric patients, APOKYN for the acute treatment of hypomobility in advanced Parkinson’s Disease (PD), and XADAGO for managing off episodes in PD patients on levodopa/carbidopa therapy. Furthermore, MYOBLOC is utilized for cervical dystonia and sialorrhea, GOCOVRI addresses dyskinesia associated with PD, and Osmolex ER is indicated for Parkinson's disease and drug-induced extrapyramidal reactions in adults. The operating income ratio is 0.12 indicating the company's operational profitability margin, while the earnings per share (EPS) is noted at $1.34 reflecting profitability on a per-share basis. Additionally, the EBITDA ratio stands at 0.27 highlighting the company's operational efficiency. Beyond commercial products, the company has promising candidates in its pipeline, including Qelbree (SPN-812), which has completed Phase III trials for ADHD treatment, and SPN-830, a late-stage drug/device combination for PD off episodes, among others. The stock is affordable at $31.82 making it suitable for budget-conscious investors. Despite this affordability, the stock experiences a low average trading volume of 560,381.00 indicating lower market activity. With a market capitalization of $1,790,547,408.00 the company is classified as a small-cap player in the pharmaceutical landscape. It is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth. This combination of market positioning and strategic focus allows Supernus Pharmaceuticals to continue making an impact in the CNS treatment arena.
Is Supernus Pharmaceuticals, Inc. (SUPN) a good investment?
Investing in Supernus Pharmaceuticals, Inc. (SUPN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is Supernus Pharmaceuticals, Inc. (SUPN)'s stock forecast?
Analysts predict Supernus Pharmaceuticals, Inc. stock to fluctuate between $25.66 (low) and $40.28 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Supernus Pharmaceuticals, Inc.'s market capitalization?
As of 2025-07-03, Supernus Pharmaceuticals, Inc.'s market cap is $1,790,547,408, based on 55,989,600 outstanding shares.
How does Supernus Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Supernus Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Supernus Pharmaceuticals, Inc. (SUPN) stock?
To buy Supernus Pharmaceuticals, Inc. (SUPN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SUPN. Place an order (Market, Limit, etc.).
What is the best time to invest in Supernus Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Supernus Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $661,817,000 | EPS: $1.34 | Growth: 5,460.17%.
Where can I find Supernus Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.supernus.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Supernus Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Supernus Pharmaceuticals, Inc. stock?
All-time high: $42.09 (2023-02-02) | All-time low: $21.99 (2023-10-27).
What are the key trends affecting Supernus Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay's ADHD symptom management New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay's ADHD symptom management
zacks.com
Investors in Supernus Pharmaceuticals, Inc. SUPN need to pay close attention to the stock based on moves in the options market lately. That is because the June 20, 2025 $30 Call had some of the highest implied volatility of all equity options today.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
seekingalpha.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Peter Vozzo - Investor Relations-ICR Healthcare Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen David Amsellem - Piper Sandler Operator Good afternoon and welcome to Supernus Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
zacks.com
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
See all news
